ERRATA

Page Number	Title	Section	Description
USP 34–NF 29			
309	⟨741⟩ *Melting Range or Temperature*		Line 26: Change "Five" to: Eight
407	⟨921⟩ *Water Determination*	*Method 1a (Direct Titration)*	Line 22 under *Standardization of the Reagent*: Change "For sodium tartrate, quickly add 20 to 125 mg of sodium tartrate ($C_4H_4Na_2O_6 \cdot 2H_2O$), accurately weighed by difference, and titrate to the endpoint." to: For sodium tartrate dihydrate, quickly add 20 to 125 mg of sodium tartrate dihydrate ($C_4H_4Na_2O_6 \cdot 2H_2O$), accurately weighed by difference, and titrate to the endpoint.
954	*Tetrahydro-2-furancarboxylic Acid*		Line 3: Change "[NOTE—A suitable grade is available from www.sigma-aldrich.com, catalog number 345117.]" to: [NOTE—A suitable grade is available from www.sigma-aldrich.com, catalog number 341517.]
1125	*Echinacea purpurea Aerial Parts*	*Botanical characteristics*	Line 3 under *Leaf*: Change "abundant on the dorsal surface and fewer on the ventral surface" to: abundant on the ventral surface and fewer on the dorsal surface
1166	*Glucosamine Tablets*	*Assay*	Line 3 under *Assay preparation*: Change "80 mg" to: 312 mg
1167	*Glucosamine Sulfate Potassium Chloride*	*Assay*	Line 1 under *Assay preparation*: Change "187.5 mg" to: 263 mg
1167	*Glucosamine Sulfate Sodium Chloride*	*Assay*	Line 1 under *Assay preparation*: Change "187.5 mg" to: 250 mg
1323	*Oil- and Water-Soluble Vitamins with Minerals Tablets*	STRENGTH *Cholecalciferol or Ergocalciferol (Vitamin D), Method 3*	Line 6 under *Analysis*: Change "Result = $(r_U/r_S) \times (C_S/C_U) \times F \times 100$" to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
			Line 16 under *Analysis*: Delete "F = correction factor to account for the average amount of previtamin D present in the *Sample solution*, 1.09"
1520	*Erythritol*	*USP Reference standards* ⟨11⟩	Change "USP Erythritol RS" to: USP Erythritol RS *meso*-Erythritol, 1,2,3,4-butanetetrol. $C_4H_{10}O_4$ 122.12
1969	*Azithromycin for Injection*	*USP Reference standards* ⟨11⟩	Line 12: Add "USP Desosaminylazithromycin RS"
1971	*Azithromycin for Oral Suspension*	*USP Reference standards* ⟨11⟩	Line 1: Add "USP Azaerythromycin RS"
2488	*Desflurane*	IMPURITIES *Organic Impurities*	Line 12 under *Analysis*: Change "r_U = peak response of the Desflurane used as the solvent r_S = peak response of the *Standard solution*" to: r_U = peak response of each impurity from the Desflurane used as the solvent r_S = peak response of each impurity from the *Standard solution*

Page Number	Title	Section	Description
2488	*Desflurane*	IMPURITIES *Organic Impurities*	Line 21 under *Analysis*: Change "r_U = peak response of the *Sample solution* r_S = peak response of the *Standard solution* C_F = final concentration in the *Standard solution* (%)" to: r_U = peak response of each impurity from the *Sample solution* r_S = peak response of each impurity from the *Standard solution* C_F = final concentration of each impurity in the *Standard solution* (%)
			Line 26 under *Analysis*: Change "r_U = peak response of the *Sample solution* r_S = peak response of the *Standard solution*" to: r_U = peak response of each impurity from the *Sample solution* r_S = peak response of Isoflurane from the *Standard solution*
2610	*Divalproex Sodium*	*USP Reference standards* ⟨11⟩	Line 2: Change "USP Divalproex Sodium RS Pentanoic acid, 2-propyl-, sodium salt (2 : 1). $(C_{16}H_{31}NaO_4)_n$ Repeating unit molecular weight, 310.41" to: USP Divalproex Sodium RS Sodium hydrogen bis(2-propylvalerate), oligomer; pentanoic acid, 2-propyl-, sodium salt (2 : 1). $(C_{16}H_{31}NaO_4)_n$ 310.41
2782	*Etidronate Disodium*	*USP Reference standards* ⟨11⟩	Change "USP Etidronate Disodium Related Compound A RS Sodium phosphite dibasic pentahydrate. $Na_2HPO_3 \cdot 5H_2O$ 216.04" to: USP Etidronate Disodium Related Compound A RS Sodium phosphite dibasic pentahydrate. $Na_2HPO_3 \cdot 5H_2O$ 216.04 [CAS-13708-85-5]
2789	*Etoposide Capsules*	*USP Reference standards* ⟨11⟩	Change: "USP Etoposide Related Compound A RS" to: USP Etoposide Resolution Mixture RS
2790	*Etoposide Injection*	*USP Reference standards* ⟨11⟩	Change: "USP Etoposide Related Compound A RS" to: USP Etoposide Resolution Mixture RS
2890	*Flurazepam Hydrochloride*	*USP Reference standards* ⟨11⟩	Change "USP Fluphenazine Enanthate RS" to: USP Flurazepam Hydrochloride RS
2891	*Flurazepam Hydrochloride Capsules*	*USP Reference standards* ⟨11⟩	Change "USP Fluphenazine Enanthate RS" to: USP Fluphenazine Hydrochloride RS
3275	*Letrozole Tablets*	*Assay*	Line 1 under *Sample solution*: Change "10 µg/mL of letrozole in *Diluent*, from *Sample stock solution*" to: 10 µg/mL of letrozole in *Mobile phase*, from *Sample stock solution*
3581	*Mycophenolate Mofetil Tablets*	IMPURITIES *Procedure 3: Limit of Z-Mycophenolate Mofetil*	Line 3 under *System Suitability*: Change "[NOTE—The relative retention times for mycophenolate mofetil and mycophenolate *Z*-mycophenolate mofetil are 1.0 and 1.1, respectively.]" to: [NOTE—The relative retention times for mycophenolate mofetil and *Z*-mycophenolate mofetil are 1.0 and 1.1, respectively.]
3656	*Nifedipine*	*USP Reference standards* ⟨11⟩	Line 11: Add "[NOTE—Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenylpyridine derivative. Exposure to UV light leads to the formation of a nitrophenylpyridine derivative. Perform assays and tests in the dark or under golden fluorescent or other low-actinic light. Use low-actinic glassware.]"
3658	*Nifedipine Capsules*	*USP Reference standards* ⟨11⟩	Line 11: Add "[NOTE—Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenylpyridine derivative. Exposure to UV light leads to the formation of a nitrophenylpyridine derivative. Perform assays and tests in the dark or under golden fluorescent or other low-actinic light. Use low-actinic glassware.]"

Page Number	Title	Section	Description
3698	*Nystatin Oral Suspension*	*Uniformity of dosage units* ⟨905⟩	Line 1 under *Procedure for content uniformity*: Change "[NOTE—Use low-actinic glassware. The correction factor, *F*, calculated as directed in section (4) of *Content Uniformity* under *Uniformity of Dosage Units* ⟨905⟩, is invalid if the value obtained by the formula in the second sentence is greater than 25; follow sections (5) and (6), except to substitute 0.750 for 0.900.]" to: [NOTE—Use low-actinic glassware.]
3749	*Oxaliplatin for Injection*	IMPURITIES *Procedure 3: Limit of Related Compound C and Unspecified Impurities*	Line 7 under *Procedure 3*: Change "*Mobile phase* and *Chromatographic system*:" to: *Mobile phase*:
			Line 25 under *Procedure 3*: Add "*Chromatographic system*: Proceed as directed in the *Assay*, except for the Injection size. *Injection size*: 10 µL"
3758	*Oxazepam Tablets*	*Assay*	Line 1: Change "Weigh and finely powder not less than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 50 mg of oxazepam, to a medium-porosity, sintered-glass funnel that is fitted into a small suction flask, and proceed as directed in the *Assay* under *Oxazepam Capsules*, beginning with "Add 25 mL of alcohol."" to: Weigh and finely powder not less than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 50 mg of oxazepam, to a medium-porosity, sintered-glass funnel that is fitted into a small suction flask. Add 25 mL of alcohol, mix with the aid of a stirring rod, and after about 5 minutes apply gentle suction to remove the extract. Repeat the extraction with four additional 25-mL portions of alcohol, transfer the extracts to a 250-mL volumetric flask, dilute with alcohol to volume, and mix. Transfer 2.0 mL of this solution to a 100-mL volumetric flask, dilute with alcohol to volume, and mix. Concomitantly determine the absorbances of this solution and of a Standard solution of USP Oxazepam RS in the same medium having a known concentration of about 4 µg per mL in 1-cm cells at the wavelength of maximum absorbance at about 229 nm, with a suitable spectrophotometer, using alcohol as the blank.
3808	*Pancuronium Bromide*	*USP Reference standards* ⟨11⟩	Line 2: Delete 3α, 17β-dihydroxy-2β, 16β-dipiperidinyl-5α-androstane,3,17-diacetate,dimethobromide. $C_{35}H_{60}Br_2N_2O_4$ 732.67
4168	*Risedronate Sodium Tablets*	*Assay*	Line 6 under *Assay preparation*: Change "0.5–1.5 g per mL" to: 0.5–1.5 mg per mL
4226	*Simethicone Emulsion*	IDENTIFICATION *Infrared Absorption* ⟨197S⟩	Line 4 under *Analysis*: Delete "Place about 5 drops of the *Sample solution* in the sample trough, and dry it with a stream of nitrogen."
4436	*Ticlopidine Hydrochloride*	SPECIFIC TESTS *Limit of Formaldehyde*	Line 1 under *Sample solution*: Change "50 mg/mL of Ticlopidine Hydrochloride in methanol" to: 0.50 g of Ticlopidine Hydrochloride in 10 mL methanol
4477	*Trandolapril*	*Related compounds*	Line 7 under *Chromatographic system*: Change "Chromatograph the *Resolution solution*, and record the responses as directed for *Procedure*: the resolution, *R*, between the peaks due to trandolapril related compound C and trandolapril related compound D is not less than 4; the tailing factor is ≤1.5; and the relative standard deviation for replicate injections is not more than 3.0%. to: Chromatograph the *Resolution solution*, and record the responses as directed for *Procedure*: the resolution, *R*, between the peaks due to trandolapril related compound C and trandolapril related compound D is not less than 4. Chromatograph the *Standard solution*, and record the responses as directed for *Procedure*: the tailing factor is 1.5; and the relative standard deviation for replicate injections is not more than 3.0%.

Page Number	Title	Section	Description
4564	*Vancomycin*	*Chromatographic purity*	Change: "*Triethylamine buffer, Solution A, Solution B, Mobile phase, Resolution solution,* and *Chromatographic system*—Prepare as directed in the test for *Chromatographic purity* under *Vancomycin Hydrochloride* *Test preparation A*—Transfer about 250 mg of Vancomycin to a 25-mL volumetric flask, add 5 mL of *Solution A*, then add 0.1 N hydrochloric acid dropwise with swirling until dissolution is achieved. Dilute with *Solution A* to volume, and mix. *Test preparation B*—Transfer 2.0 mL of *Test preparation A* to a 50-mL volumetric flask, dilute with *Solution A* to volume, and mix. *Procedure*—Proceed as directed for *Procedure* in the test for *Chromatographic purity* under *Vancomycin Hydrochloride*. Calculate the percentage of vancomycin B in the specimen taken by the formula: $2500r_B / (25r_B + r_A)$ in which the terms are as defined therein: not less than 92% of vancomycin B is found. Calculate the percentage of any individual peak, other than the main peak, by the formula: $100r_{Ai} / (25r_B + r_A)$ in which the terms are as defined therein: not more than 3% of any peak other than the main peak is found." to: *Triethylamine buffer*—Mix 4 mL of triethylamine and 2000 mL of water, and adjust with phosphoric acid to a pH of 3.2. *Solution A*—Prepare a mixture of *Triethylamine buffer*, acetonitrile, and tetrahydrofuran (92 : 7 : 1), and degas briefly. *Solution B*—Prepare a suitable mixture of *Triethylamine buffer*, acetonitrile, and tetrahydrofuran (70 : 29 : 1), and degas briefly. *Mobile phase*—Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under *Chromatography* ⟨621⟩), changing the acetonitrile proportion in *Solution A* to obtain a retention time of 7.5 to 10.5 minutes for the main vancomycin peak. *Resolution solution*—Prepare a solution of USP Vancomycin Hydrochloride RS in water containing 0.5 mg per mL, heat at 65° for 48 hours, and allow to cool. *Test preparation A*—Transfer about 250 mg of Vancomycin to a 25-mL volumetric flask, add 5 mL of *Solution A*, then add 0.1 N hydrochloric acid dropwise with swirling until dissolution is achieved. Dilute with *Solution A* to volume, and mix. *Test preparation B*—Transfer 2.0 mL of *Test preparation A* to a 50-mL volumetric flask, dilute with *Solution A* to volume, and mix. *Chromatographic system* (see *Chromatography* ⟨621⟩)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 2 mL per minute. The chromatograph is programmed as follows. Time (minutes) / *Solution A* (%) / *Solution B* (%) / Elution 0-12 / 100 / 0 / isocratic 12-20 / 100→0 / 0→100 / linear gradient 20-22 / 0 / 100 / isocratic 22-23 / 0→100 / 100→0 / linear gradient 23-30 / 100 / 0 / isocratic Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure:* the elution order is resolution compound 1, vancomycin B, and resolution compound 2. Resolution compound 2 elutes 3 and 6 minutes after the start of the period when the percentage of *Solution B* is increasing from 0% to 100%. The resolution, *R*, between resolution compound 1 and vancomycin B is not less than 3.0; and the column efficiency, calculated from the vancomycin B peak, is not less than 1500 theoretical plates. *Procedure*—[NOTE—Where baseline separation is not achieved, peak areas are defined by vertical lines extended from the valleys between peaks to the baseline. The main component peak may include a fronting shoulder, which is attributed to monodechlorovancomycin. This shoulder should not be integrated separately.] Separately inject equal volumes (about 20 µL) of *Test preparation A*

Page Number	Title	Section	Description
4564	*Vancomycin*	*Chromatographic purity, continued*	and *Test preparation B* into the chromatograph, record the chromatograms, and measure the area responses for all of the peaks. [NOTE—Correct any peak observed in the chromatograms obtained from *Test preparation A* and *Test preparation B* by subtracting the area response of any peak observed in the chromatogram of Solution A at the corresponding elution time.] Calculate the percentage of vancomycin B in the specimen tested by the formula: $2500r_B / (25r_B + r_A)$ in which r_B is the corrected area response of the main peak obtained in the chromatogram of *Test preparation B*; and r_A is the sum of the corrected area responses of all the peaks, other than the main peak, in the chromatogram obtained from *Test preparation A*: not less than 92% of vancomycin B is found. Calculate the percentage of each other peak taken by the formula: $100r_{Ai} / (25r_B + r_A)$ in which r_{Ai} is the corrected area response of any individual peak, other than the main peak, obtained in the chromatogram of *Test preparation A*: not more than 3% of any peak other than the main peak is found.
4567	*Vancomycin Injection*	*Chromatographic purity*	Change: "*Triethylamine buffer, Solution A, Solution B, Mobile phase,* and *Chromatographic system*—Prepare as directed in the test for *Chromatographic purity* under *Vancomycin Hydrochloride*. *Resolution solution*—Allow a container of Injection to thaw, and mix the solution. Dilute a portion of the solution with water to obtain a solution containing 0.5 mg of vancomycin per mL, heat at 65° for 24 hours, and allow to cool. *Test preparation A*—Allow a container of Injection to thaw, and mix the solution. *Test preparation B*—Transfer 2.0 mL of *Test preparation A* to a 50-mL volumetric flask, dilute with *Solution A* to volume, and mix. *Procedure*—Proceed as directed for *Procedure* in the test for *Chromatographic purity* under *Vancomycin Hydrochloride*. Calculate the percentage of vancomycin B in the specimen taken by the formula: $2500r_B / (25r_B + r_A)$ in which the terms are as defined therein: not less than 88% of vancomycin B is found. Calculate the percentage of any individual peak, other than the main peak, by the formula: $100r_{Ai} / (25r_B + r_A)$ in which the terms are as defined therein: not more than 4% of any peak other than the main peak is found." to: *Triethylamine buffer*—Mix 4 mL of triethylamine and 2000 mL of water, and adjust with phosphoric acid to a pH of 3.2. *Solution A*—Prepare a mixture of *Triethylamine buffer*, acetonitrile, and tetrahydrofuran (92 : 7 : 1), and degas briefly. *Solution B*—Prepare a suitable mixture of *Triethylamine buffer*, acetonitrile, and tetrahydrofuran (70 : 29 : 1), and degas briefly. *Mobile phase*—Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under *Chromatography* ⟨621⟩), changing the acetonitrile proportion in *Solution A* to obtain a retention time of 7.5 to 10.5 minutes for the main vancomycin peak. *Resolution solution*—Allow a container of Injection to thaw, and mix the solution. Dilute a portion of the solution with water to obtain a solution containing 0.5 mg of vancomycin per mL, heat at 65° for 24 hours, and allow to cool. *Test preparation A*—Allow a container of Injection to thaw, and mix the solution. *Test preparation B*—Transfer 2.0 mL of *Test preparation A* to a 50-mL volumetric flask, dilute with *Solution A* to volume, and mix. *Chromatographic system* (see *Chromatography* ⟨621⟩)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 2 mL per minute. The chromatograph is programmed as follows.

Page Number	Title	Section	Description
4567	*Vancomycin Injection*	*Chromatographic purity, continued*	Time (minutes) / *Solution A* (%) / *Solution B* (%) / Elution 0-12 / 100 / 0 / isocratic 12-20 / 100→0 / 0→100 / linear gradient 20-22 / 0 / 100 / isocratic 22-23 / 0→100 / 100→0 / linear gradient 23-30 / 100 / 0 / isocratic Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the elution order is resolution compound 1, vancomycin B, and resolution compound 2. Resolution compound 2 elutes 3 and 6 minutes after the start of the period when the percentage of *Solution B* is increasing from 0% to 100%. The resolution, *R*, between resolution compound 1 and vancomycin B is not less than 3.0; and the column efficiency, calculated from the vancomycin B peak, is not less than 1500 theoretical plates. *Procedure*—[NOTE—Where baseline separation is not achieved, peak areas are defined by vertical lines extended from the valleys between peaks to the baseline. The main component peak may include a fronting shoulder, which is attributed to monodechlorovancomycin. This shoulder should not be integrated separately.] Separately inject equal volumes (about 20 µL) of *Test preparation A* and *Test preparation B* into the chromatograph, record the chromatograms, and measure the area responses for all of the peaks. [NOTE—Correct any peak observed in the chromatograms obtained from *Test preparation A* and *Test preparation B* by subtracting the area response of any peak observed in the chromatogram of *Solution A* at the corresponding elution time.] Calculate the percentage of vancomycin B in the specimen tested by the formula: $2500r_B / (25r_B + r_A)$ in which r_B is the corrected area response of the main peak obtained in the chromatogram of *Test preparation B*; and r_A is the sum of the corrected area responses of all the peaks, other than the main peak, in the chromatogram obtained from *Test preparation A*: not less than 88% of vancomycin B is found. Calculate the percentage of each other peak taken by the formula: $100r_{Ai} / (25r_B + r_A)$ in which r_{Ai} is the corrected area response of any individual peak, other than the main peak, obtained in the chromatogram of *Test preparation A*: not more than 4% of any peak other than the main peak is found.
4596	*Water for Injection*	ADDITIONAL REQUIREMENTS	Line 1: Change "[NOTE—Required for bulk and packaged forms of *Water for Injection*.]" to: [NOTE—Required for packaged forms of *Water for Injection*.]
4598	*Purified Water*	MONOGRAPH TITLE	Line 1: Change "[NOTE—Required for bulk and packaged forms of *Purified Water*]" to: [NOTE—For microbiological guidance, see general information chapter *Water for Pharmaceutical Purposes* ⟨1231⟩.]
		DEFINITION	Line 1: Delete "[NOTE—For microbiological guidance, see general information chapter *Water for Pharmaceutical Purposes* ⟨1231⟩.]"
		SPECIFIC TESTS	Line 1: Add "[NOTE—Required for bulk and packaged forms of *Purified Water*]"
4623	*Zinc Carbonate*	*Insoluble matter*	Line 5: Change "20 mg" to: 2 mg
4636	*Zolpidem Tartrate Extended-Release Tablets*	*USP Reference standards* ⟨11⟩	Change "USP Zonisamide Related Compound A RS 1,2-Benzisoxazole-3-methanesulfonic acid sodium salt. $C_8H_6NNaO_4S$ 235.19 [CAS-73101-64-1]" to: USP Zolpidem Related Compound A RS *N*,*N*-Dimethyl-2-(7methyl-2-p-tolylimidazo[1,2-*a*]pyridin-3-yl)acetamide. $C_{19}H_{21}N_3O$ 307.39

Page Number	Title	Section	Description
First Supplement to USP 34–NF 29			
5034	*Tamsulosin Hydrochloride Capsules*	PERFORMANCE TESTS *Dissolution, Test 8*	Line 1 under *Apparatus 2*: Change "50 rpm, with sinkers" to: 100 rpm, with sinkers